Neuberger Berman Group’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-561,141
| Closed | -$5.29M | – | 2003 |
|
|
2024
Q4 | $5.29M | Sell |
561,141
-200,589
| -26% | -$2.08M | ﹤0.01% | 950 |
|
|
2024
Q3 | $8.14M | Sell |
761,730
-80
| -0% | -$871 | 0.01% | 836 |
|
|
2024
Q2 | $7.56M | Buy |
761,810
+293,158
| +63% | +$3.01M | 0.01% | 821 |
|
|
2024
Q1 | $5.52M | Sell |
468,652
-249,062
| -35% | -$3.19M | ﹤0.01% | 899 |
|
|
2023
Q4 | $10.2M | Buy |
717,714
+171,029
| +31% | +$1.94M | 0.01% | 768 |
|
|
2023
Q3 | $6.65M | Buy |
546,685
+4,200
| +0.8% | +$54.2K | 0.01% | 820 |
|
|
2023
Q2 | $6.81M | Buy |
542,485
+217,430
| +67% | +$2.58M | 0.01% | 826 |
|
|
2023
Q1 | $3.6M | Buy |
325,055
+14,819
| +5% | +$183K | ﹤0.01% | 948 |
|
|
2022
Q4 | $3.79M | Sell |
310,236
-162,158
| -34% | -$1.83M | ﹤0.01% | 926 |
|
|
2022
Q3 | $4.93M | Sell |
472,394
-3,609
| -0.8% | -$40.2K | 0.01% | 885 |
|
|
2022
Q2 | $5.11M | Buy |
476,003
+32,027
| +7% | +$264K | 0.01% | 891 |
|
|
2022
Q1 | $4.2M | Buy |
443,976
+14,609
| +3% | +$137K | ﹤0.01% | 1007 |
|
|
2021
Q4 | $4.87M | Buy |
+429,367
| New | +$4.79M | ﹤0.01% | 986 |
|
|
2021
Q1 | – | Sell |
-163,011
| Closed | -$3.76M | – | 1785 |
|
|
2020
Q4 | $3.76M | Sell |
163,011
-66,989
| -29% | -$1.37M | ﹤0.01% | 981 |
|
|
2020
Q3 | $3.25M | Hold |
230,000
| – | – | ﹤0.01% | 960 |
|
|
2020
Q2 | $3.47M | Buy |
230,000
+10,000
| +5% | +$122K | ﹤0.01% | 890 |
|
|
2020
Q1 | $2.03M | Hold |
220,000
| – | – | ﹤0.01% | 941 |
|
|
2019
Q4 | $2.14M | Sell |
220,000
-92,300
| -30% | -$845K | ﹤0.01% | 1016 |
|
|
2019
Q3 | $2.5M | Sell |
312,300
-20,000
| -6% | -$217K | ﹤0.01% | 966 |
|
|
2019
Q2 | $4.15M | Buy |
332,300
+122,300
| +58% | +$1.55M | 0.01% | 889 |
|
|
2019
Q1 | $2.86M | Buy |
210,000
+24,000
| +13% | +$293K | ﹤0.01% | 922 |
|
|
2018
Q4 | $1.78M | Buy |
186,000
+56,000
| +43% | +$616K | ﹤0.01% | 1004 |
|
|
2018
Q3 | $1.57M | Buy |
130,000
+40,000
| +44% | +$559K | ﹤0.01% | 1086 |
|
|
2018
Q2 | $1.41M | Buy |
90,000
+30,000
| +50% | +$454K | ﹤0.01% | 1136 |
|
|
2018
Q1 | $902K | Sell |
60,000
-6,000
| -9% | -$91.3K | ﹤0.01% | 1211 |
|
|
2017
Q4 | $950K | Buy |
66,000
+53,000
| +408% | +$728K | ﹤0.01% | 1227 |
|
|
2017
Q3 | $196K | Buy |
+13,000
| New | +$172K | ﹤0.01% | 1541 |
|
|
2016
Q1 | – | Sell |
-10,766
| Closed | -$104K | – | 1492 |
|
|
2015
Q4 | $104K | Sell |
10,766
-57,177
| -84% | -$515K | ﹤0.01% | 1466 |
|
|
2015
Q3 | $951K | Sell |
67,943
-6,757
| -9% | -$106K | ﹤0.01% | 1171 |
|
|
2015
Q2 | $1.06M | Buy |
74,700
+14,700
| +25% | +$177K | ﹤0.01% | 1198 |
|
|
2015
Q1 | $653K | Sell |
60,000
-30,000
| -33% | -$264K | ﹤0.01% | 1293 |
|
|
2014
Q4 | $748K | Buy |
+90,000
| New | +$618K | ﹤0.01% | 1280 |
|
Other funds holding FOLD
PA
ACA
RG
PAI
Neuberger Berman Group's FOLD Position: Q1 2025 in Review
Neuberger Berman Group sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 561,141 shares — an estimated $5.29M sold.
Neuberger Berman Group first reported a position in FOLD in Q4 2014 and held it in 32 quarters. The position peaked at $10.2M in Q4 2023. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.
- Neuberger Berman Group reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
- Neuberger Berman Group sold 561,141 Amicus Therapeutics shares in Q1 2025, an estimated $5.29M.
- Neuberger Berman Group first reported a position in Amicus Therapeutics in Q4 2014 and held it in 32 quarters.
- Neuberger Berman Group's Amicus Therapeutics position peaked at $10.2M in Q4 2023.
- 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.
Based on Neuberger Berman Group's 13F filing for Q1 2025, filed 13 May 2025.